Disclosed are compounds that are bradykinin B.sub.1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B.sub.1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.